CAPTRUST Financial Advisors
ATRA icon

CAPTRUST Financial Advisors’s Atara Biotherapeutics ATRA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,323
Closed -$42.6K – 2178
2023
Q4 		$42.6K Buy
3,323
+2,602
+361% +$60.7K ﹤0.01% 2600
2023
Q3 		$26.7K Buy
+721
New +$32.1K ﹤0.01% 2515
2023
Q2 		– Sell
-412
Closed -$29.9K – 2531
2023
Q1 		$29.9K Buy
+412
New +$40K ﹤0.01% 2235
2022
Q3 		– Sell
-8
Closed -$2K – 2215
2022
Q2 		$2K Sell
8
-1
-11% -$163 ﹤0.01% 4425
2022
Q1 		$2K Sell
9
-2
-18% -$637 ﹤0.01% 4456
2021
Q4 		$4K Hold
11
– – ﹤0.01% 4157
2021
Q3 		$5K Buy
11
+1
+10% +$358 ﹤0.01% 3932
2021
Q2 		$4K Sell
10
-1
-9% -$357 ﹤0.01% 3932
2021
Q1 		$4K Buy
+11
New +$4.86K ﹤0.01% 3793

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

CAPTRUST Financial Advisors's ATRA Position: Q1 2024 in Review

CAPTRUST Financial Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 3,323 shares — an estimated $42.6K sold.

CAPTRUST Financial Advisors first reported a position in ATRA in Q1 2021 and held it in 9 quarters. The position peaked at $42.6K in Q4 2023. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

  • CAPTRUST Financial Advisors reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 3,323 Atara Biotherapeutics shares in Q1 2024, an estimated $42.6K.
  • CAPTRUST Financial Advisors first reported a position in Atara Biotherapeutics in Q1 2021 and held it in 9 quarters.
  • CAPTRUST Financial Advisors's Atara Biotherapeutics position peaked at $42.6K in Q4 2023.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2024, filed 15 May 2024.